Development of adverse outcome pathways relevant for the identification of substances having endocrine disruption properties Uterine adenocarcinoma as adverse outcome

Development of adverse outcome pathways (AOPs) for uterine adenocarcinoma can provide a practical tool to implement the EFSA‐ECHA Guidance (2018) for the identification of endocrine disruptors in the context of Regulations (EU) No 528/2012 and (EC) No 1107/2009. AOPs can give indications about the s...

Descripción completa

Detalles Bibliográficos
Autores principales: Hernandez‐Jerez, Antonio F, Adriaanse, Paulien, Aldrich, Annette, Berny, Philippe, Coja, Tamara, Duquesne, Sabine, Focks, Andreas, Millet, Maurice, Pelkonen, Olavi, Pieper, Silvia, Tiktak, Aaldrik, Topping, Christopher J, Widenfalk, Anneli, Wilks, Martin, Wolterink, Gerrit, Angeli, Karine, Recordati, Camilla, Van Durseen, Majorie, Aiassa, Elisa, Lanzoni, Anna, Lostia, Alfonso, Martino, Laura, Guajardo, Irene Pilar Munoz, Panzarea, Martina, Terron, Andrea, Marinovich, Marina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Scientific Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9926893/
https://www.ncbi.nlm.nih.gov/pubmed/36818642
http://dx.doi.org/10.2903/j.efsa.2023.7744

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9926893/
https://www.ncbi.nlm.nih.gov/pubmed/36818642
http://dx.doi.org/10.2903/j.efsa.2023.7744

Ejemplares similares